Faricimab in Previously Treated Eyes With Neovascular Age-Related Macular Degeneration : An Assessment of Durability and Treatment Outcomes

BACKGROUND AND OBJECTIVE: This study evaluated the efficacy and durability of faricimab in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with anti-vascular endothelial growth factor (anti-VEGF) agents

Détails bibliographiques
Publié dans:Ophthalmic surgery, lasers & imaging retina. - 2013. - 55(2024), 9 vom: 15. Sept., Seite 504-509
Auteur principal: Shaheen, Abdulla (Auteur)
Autres auteurs: Ashkenazy, Noy, Magraner, Maria, Patel, Nimesh A, Fortun, Jorge, Rosenfeld, Philip J, Schwartz, Stephen G, Haddock, Luis J, Dubovy, Sander R, Sridhar, Jayanth, Yehoshua, Zohar, Kovach, Jaclyn L, Townsend, Justin H, Smiddy, William E, Flynn, Harry W Jr, Yannuzzi, Nicolas A
Format: Article en ligne
Langue:English
Publié: 2024
Accès à la collection:Ophthalmic surgery, lasers & imaging retina
Sujets:Journal Article Angiogenesis Inhibitors Vascular Endothelial Growth Factor A VEGFA protein, human Ranibizumab ZL1R02VT79 Antibodies, Monoclonal, Humanized Immunoglobulin Fab Fragments